Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

oncoprescribe-top

Advertisement

Tag: Cutaneous T-Cell Lymphoma

POTELIGEO® (Mogamulizumab-kpkc)

September 16, 2018April 5, 2020 RR

The FDA on August 8, 2018 approved POTELIGEO® for adult patients with Relapsed or Refractory Mycosis Fungoides (MF) or Sézary Syndrome (SS) after at least one prior systemic therapy. POTELIGEO® is a product of Kyowa Kirin, Inc.

Ad 1

oncoprescribe-ad

Advertisement

Ad 2

OncoPrescribe

Advertisement

Ad 3

OncoPrescribe.com-Ad

Advertisement

Ad 4

Immunization Schedule

Advertisement

  • HELP
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved